Zacks Investment Research downgraded Coherent, Inc. (NASDAQ:COHR) to Hold in a report released today.
- Updated: September 27, 2016
Zacks Investment Research has downgraded Coherent, Inc. (NASDAQ:COHR) to Hold in a report released on Tuesday September 27, 2016.
Previously on 5/23/2016, Benchmark reported on Coherent, Inc. (NASDAQ:COHR) raised the target price from $110.00 to $115.00. At the time, this indicated a possible upside of 0.30%.
Yesterday Coherent, Inc. (NASDAQ:COHR) traded -0.09% lower at $110.69. COHR’s 50-day average is $107.62 and its two hundred day average is $96.76. With the last stock price close up 14.39% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 63,298 shares of the stock were exchanged, down from an average trading volume of 186,270
See Chart Below
Coherent, Inc. has a price-earnings ratio of 32.21 with a one year low of $52.15 and a one year high of $112.40 COHR’s total market value is presently $0.
A total of 5 analysts have released a report on Coherent, Inc.. Two analysts rating the company a strong buy, three analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $110.60.
More About Coherent, Inc. (NASDAQ:COHR)
Coherent, Inc. is a supplier of photonics-based solutions in a range of commercial and scientific research applications. The Company designs, manufactures, services and markets lasers, laser tools and related accessories for a diverse group of customers. It operates through two operating segments: Specialty Lasers and Systems (SLS) and Commercial Lasers and Components (CLC). The SLS segment develops and manufactures configurable, advanced performance products serving the microelectronics, scientific research and government programs, and original equipment manufacturer (OEM) components and instrumentation markets. The CLC segment focuses on products that are offered in set configurations. Its portfolio of lasers that address the scientific research market includes its Chameleon, COMPexPro, Evolution, Fidelity, Legend, Libra, MBD, MBR, Monaco, Vitara, Mephisto, Mira and Verdi lasers. It also provides ultrafast lasers for use in cataract surgery.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.